These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 19515449)
1. A short cut to predict the clinical response to beta-blocker therapy in cirrhosis? Merkel C J Hepatol; 2009 Aug; 51(2):268-70. PubMed ID: 19515449 [No Abstract] [Full Text] [Related]
2. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930 [TBL] [Abstract][Full Text] [Related]
3. The haemodynamic response to propranolol in cirrhosis with arterial hypertension: a comparative analysis with normotensive cirrhotic patients. Sharma P; Kumar A; Jha S; Mishra SR; Sharma BC; Sarin SK Aliment Pharmacol Ther; 2010 Jul; 32(1):105-12. PubMed ID: 20345511 [TBL] [Abstract][Full Text] [Related]
4. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as guidance for prophylaxis and treatment of bleeding and re-bleeding? Yes! Merkel C; Montagnese S Eur J Intern Med; 2011 Feb; 22(1):1-4. PubMed ID: 21238883 [TBL] [Abstract][Full Text] [Related]
5. Preventing the development of varices in cirrhosis. Garcia-Tsao G J Clin Gastroenterol; 2007; 41 Suppl 3():S300-4. PubMed ID: 17975480 [TBL] [Abstract][Full Text] [Related]
6. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as a guide for prophylaxis and therapy of bleeding and rebleeding? No. Thalheimer U; Bellis L; Puoti C; Burroughs AK Eur J Intern Med; 2011 Feb; 22(1):5-7. PubMed ID: 21238884 [TBL] [Abstract][Full Text] [Related]
7. [Treatment arterial hypertension by beta-adrenergic blockers in elderly patients with gastrointestinal disorders]. Komissarenko IA Eksp Klin Gastroenterol; 2002; (4):18-20, 130. PubMed ID: 12503267 [TBL] [Abstract][Full Text] [Related]
14. Benefits of Beta blockade beyond bleeding prophylaxis and the role of adherence. Thalheimer U; Christie J; Burroughs AK Am J Gastroenterol; 2012 Oct; 107(10):1593. PubMed ID: 23034623 [No Abstract] [Full Text] [Related]
15. [Comparative evaluation of the effectiveness of different schemes of correction the portal system pressure in patients with liver cirrhosis]. Sirchak IeS Lik Sprava; 2013; (3):32-9. PubMed ID: 25016744 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. Merkel C; Bolognesi M; Berzigotti A; Amodio P; Cavasin L; Casarotto IM; Zoli M; Gatta A J Hepatol; 2010 Jan; 52(1):45-53. PubMed ID: 19914730 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of portal hypertension. Miñano C; Garcia-Tsao G Gastroenterol Clin North Am; 2010 Sep; 39(3):681-95. PubMed ID: 20951924 [TBL] [Abstract][Full Text] [Related]
18. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. Madsen BS; Havelund T; Krag A Adv Ther; 2013 Jul; 30(7):659-70. PubMed ID: 23881723 [TBL] [Abstract][Full Text] [Related]
19. [Correction of portal hypertension by beta-adrenoblockers (atenolol and metoprolol) and inhibitors of ACE (lisinopril and enalapril) in liver cirrhosis]. Lazebnik LB; Mikheeva OM; Toporkov AS; Komissarenko IA; Vasnev OS; Fedulenkova LV Eksp Klin Gastroenterol; 2007; (5):57-66. PubMed ID: 18389599 [No Abstract] [Full Text] [Related]